Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag study
Avtorji:Hochmair, Maximilian J (Avtor)
Morabito, Alessandro (Avtor)
Hao, Desiree (Avtor)
Yang, Cheng-Ta (Avtor)
Soo, Ross A (Avtor)
Yang, James C-H (Avtor)
Gucalp, Rasim (Avtor)
Halmos, Balazs (Avtor)
Wang, Lara (Avtor)
Märten, Angela (Avtor)
Čufer, Tanja (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.
Ključne besede:non-small cell lung carcinoma - therapy, drug therapy, afatinib, osimertinib, GioTag study
Leto izida:2019
Založnik:Future Medicine Ltd
Izvor:Velika Britanija
UDK:616.2
ISSN pri članku:1744-8301
OceCobissID:521824025 Povezava se odpre v novem oknu
COBISS_ID:2048610929 Povezava se odpre v novem oknu
DOI:10.2217/fon-2019-0346 Povezava se odpre v novem oknu
Opombe:Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Tanja Cufer; Opis vira z dne 10. 1. 2020;
Število ogledov:18
Število prenosov:20
Datoteke:URL URL - Predstavitvena datoteka, za dostop obiščite https://www.futuremedicine.com/doi/full/10.2217/fon-2019-0346
 
Nadgradivo:Future oncology
Future Medicine
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:© 2019 Maximilian J Hochmair
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Začetek licenciranja:23.07.2019

Nazaj